Success of eculizumab in the treatment of atypical hemolytic uremic syndrome

Baskin E., Gulleroglu K., Kantar A., Bayrakci U., Ozkaya O.

PEDIATRIC NEPHROLOGY, vol.30, no.5, pp.783-789, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.1007/s00467-014-3003-4
  • Journal Name: PEDIATRIC NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.783-789
  • Keywords: Hemolytic anemia, Pediatric, Plasma therapy, Renal failure, Thrombocytopenia, AHUS, INVOLVEMENT, THERAPY
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Disorders of complement regulation are the most important etiology of atypical hemolytic uremic syndrome (aHUS). Recent studies demonstrate that eculizumab is beneficial in long-term aHUS treatment. We present a series of children with aHUS resistant to/dependent on plasma exchange (PE) who were treated with eculizumab.